Diabetes
Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells
Published in Medical Letter on the CDC and FDA, February 10th, 2008
Derma Sciences, Inc. (BULLETIN BOARD: DSCI) , a provider of advanced wound care products, announced that it has signed a clinical services agreement with San Luis Obispo-based, privately held U.S. Biotest, Inc. and will enter Phase II clinical development of DSC127, a novel and rapid wound-healing and scar-reduction product that has a unique mechanism of action potentially linked to the body's own, naturally occurring stem cells. The product has shown promising activity in pre-clinical animal models and has already been tested for safety in a Phase I study in humans.
Through DSC127, Derma Sciences will be able to position itself as a key player in the very large...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Depression
Selective reporting of antidepressant trials exaggerates drug effectiveness - Pediatrics
National study will look at German-made heart pump for children needing heart transplants - Atrial Fibrillation
Independent Clinical Trial Finds HIFU Surgical Ablation Effective in Treating Atrial Fibrillation - Clinical Research
Scientists at Amgen, Inc. discuss research in clinical research - Regulatory Actions
Stryker Issues Statement Regarding FDA Warning Letter - Life Sciences
Scientists at Brigham and Women's Hospital detail research in life sciences - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
